Liquidia launches Phase 3 Re-Spire trial of L606 inhaled treprostinil in PH-ILD

PUBT · 2d ago
Liquidia launches Phase 3 Re-Spire trial of L606 inhaled treprostinil in PH-ILD
  • Liquidia scheduled two posters on inhaled treprostinil programs for the ERS 2026 Congress in Barcelona on Sept. 5-9, 2026.
  • Results have not been presented yet; the posters are set for Sept. 7 and Sept. 8.
  • One presentation will outline baseline lung imaging patterns in PH-ILD patients enrolled in the ASCENT study.
  • Another will preview the Phase 3 Re-Spire trial design testing L606, a twice-daily extended-release liposomal treprostinil, in PH-ILD.
  • The update underscores a push to broaden clinical evidence supporting next-generation inhaled treprostinil options for PH-ILD.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020830PRIMZONEFULLFEED9819904) on September 02, 2026, and is solely responsible for the information contained therein.